EBIT at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's EBIT?
- Axsome Therapeutics (AXSM) reported EBIT of -$63.36M in Q1 2026.
- How has Axsome Therapeutics's EBIT changed year-over-year?
- Axsome Therapeutics's EBIT decreased by 11.2% year-over-year, from -$56.98M to -$63.36M.
- What is the long-term trend for Axsome Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EBIT has grown at a 7.5% compound annual growth rate (CAGR), from -$124.71M to -$166.76M.
- What does EBIT mean?
- Profit before interest and taxes — the business's core earning power.
- How do you interpret EBIT?
- Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
- How does EBIT compare across companies?
- Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.